PPCB Propanc Biopharma, Inc.

“we do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our limited size and early-stage nature of operations, segregation of all conflicting duties may not always be possible and may not be economically feasible;”

“The following material weaknesses in our internal control over financial reporting continued to exist at June 30, 2026: we do not have written documentation of our internal control policies and procedures.”

“management believes that, as of June 30, 2026, we did not maintain effective internal control over financial reporting based on the criteria established in the Internal Integrated Framework issued by COSO in 2013 due to certain material weaknesses in its internal controls.”

“concluded that, as of June 30, 2026 the disclosure controls and procedures of our Company were not effective to ensure that the information required to be disclosed in our Exchange Act reports was recorded, processed, summarized and reported on a timely basis due to the material weaknesses in financial reporting as discussed below.”

“our ability to successfully remediate material weaknesses in our internal controls; our ability to reach research and development milestones as planned and within proposed budgets”